Kelsey Stephen Michael 的 Form 4 申報
Revolution Medicines, Inc.RVMD,2026/11/18 申報
- 申報編號
- 0001193125-26-467372
- 申報時間
- 2026/11/18 18:23 ET
- 交易日
- 2026/11/16
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
這份申報列了 7 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $455.9 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kelsey Stephen MichaelCIK 0001462808 | 高階主管(見申報備註) |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/16 | Common Stock | M行使選擇權取得 | +27,160 | $18.56 | +$504,089.6 | 313,467 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −11,542 | $166.75F2 | −$1,924,635.43 | 301,925 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −3,627 | $167.66F3 | −$608,109.71 | 298,298 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −8,039 | $168.64F4 | −$1,355,676.86 | 290,259 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −3,052 | $169.46F5 | −$517,180.02 | 287,207 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −700 | $170.40F6 | −$119,276.99 | 286,507 | 直接 | |
| 2026/11/16 | Common Stock | S賣出處分 | −200 | $171.65 | −$34,330 | 286,307 | 直接 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/16 | Common Stock | M行使選擇權處分 | −27,160 | $0.00 | $0 | 108,640 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F2
The transaction was executed in multiple trades at prices ranging from $166.14 to $167.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The transaction was executed in multiple trades at prices ranging from $167.14 to $168.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The transaction was executed in multiple trades at prices ranging from $168.15 to $169.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The transaction was executed in multiple trades at prices ranging from $169.15 to $170.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The transaction was executed in multiple trades at prices ranging from $170.22 to $170.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Senior Advisor to the Chief Executive Officer